Craft

INmune Bio

Stock Price

$6.3

2024-10-29

Market Capitalization

$124.9 M

2024-10-29

Revenue

$50 K

FY, 2025

INmune Bio Summary

Company Summary

Overview
INmune Bio is a clinical-stage biotechnology company that develops immunotherapies that reprogram a patient’s innate immune system. It offers INKmune, an NK cell (natural killer cell) to kill cancer; INB03, a protein biologic that changes the tumor microenvironment (TME) improving the response to targeted therapies for cancer; XPro1595, a protein biologic that targets Soluble receptors for tumor necrosis factor (sTNF); etc.
Type
Public
Status
Active
Founded
2015
HQ
Boca Raton, FL, US | view all locations
Website
https://www.inmunebio.com
Cybersecurity rating
Sectors

Key People

  • Raymond J. Tesi

    Raymond J. Tesi, CEO, CMO and Chairman

  • David J. Moss
  • Mark Lowdell
  • Christopher J. Barnum

    Christopher J. Barnum, Director of Neuroscience

    LocationsView all

    1 location detected

    • Boca Raton, FL HQ

      United States

      225 NE Mizner Blvd., Suite 640

    INmune Bio Financials

    Summary Financials

    Net income (Q1, 2026)
    ($5.4M)
    Cash (Q1, 2026)
    $21.4M
    EBIT (Q1, 2026)
    ($5.8M)
    Enterprise value
    $105.1M

    Footer menu